The U.S. Food and Drug Administration (FDA) just gave the go-ahead for advanced studies on a new drug that can potentially be used to combat the effects of cocaine addiction.
Dr. Ronald Crystal, the chairman of genetic medicine at Weill Cornell, has teamed with NewYork-Presbyterian to develop a vaccine that may work as antidote of sorts for cocaine addiction. The doctors who researched the vaccine said that it can be used to blunt the harmful physiological effects of cocaine use. The way the drug works is by creating antibodies that float around in the user’s bloodstream and inhibit cocaine from reaching the brain.
To date, the new drug has been tested on rats. Now the FDA has given its backing to the researchers to conduct a clinical trial on how effective the anti-addiction drug will be when used by humans.
The funding for the study comes from the National Institutes of Health and the National Institute on Drug Abuse.
Cocaine Addiction Poses Serious Health Problems
Approximately 500,000 people end up going to emergency rooms in the US each year because of health problems related to cocaine addiction, according to data compiled by the Department of Genetic Medicine at Weill Cornell.
The development of a new anti-addiction drug could prove immensely important in the fight against drug crimes. There is not currently any meaningful solution to the problem of cocaine addiction, according to Dr. Crystal. Although there are already anti-addiction drugs like methadone that can be used to treat heroin users, the FDA has not approved a drug to treat cocaine addiction.
For additional information, read the Yahoo.com article, “Groundbreaking Treatment Could Be the End of Cocaine Addiction.”
If you or a loved one has been arrested and charged with cocaine possession, heroin possession, prescription drug possession, or any other drug crime in New Jersey, the aggressive criminal defense lawyers at Rudnick, Addonizio, Pappa & Casazza PC will help you fight the charges. Contact us now to schedule a free consultation about your case.